Zhong XP, Xia WF. Regulation of bone metabolism mediated by β-adrenergic receptor and its clinical application. World J Clin Cases 2021; 9(30): 8967-8973 [PMID: 34786380 DOI: 10.12998/wjcc.v9.i30.8967]
Corresponding Author of This Article
Wen-Fang Xia, MD, Associate Professor, Doctor, Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, Hubei Province, China. xiawenfang@hust.edu.cn
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Oct 26, 2021; 9(30): 8967-8973 Published online Oct 26, 2021. doi: 10.12998/wjcc.v9.i30.8967
Regulation of bone metabolism mediated by β-adrenergic receptor and its clinical application
Xue-Ping Zhong, Wen-Fang Xia
Xue-Ping Zhong, Wen-Fang Xia, Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
Author contributions: Zhong XP performed the majority of the writing, prepared the figure; Xia WF designed the research study and coordinated the writing of the paper; All authors have read and approve the final manuscript.
Supported byNational Natural Sciences Foundation of China, No. 81200649; Natural Sciences Foundation of Hubei Province of China, No. 2016CFB425; and Fundamental Research Funds for the Central University, No. 2016YXMS236.
Conflict-of-interest statement: The authors declare that they have no conflicting interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wen-Fang Xia, MD, Associate Professor, Doctor, Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, Hubei Province, China. xiawenfang@hust.edu.cn
Received: January 12, 2021 Peer-review started: January 12, 2021 First decision: July 5, 2021 Revised: July 18, 2021 Accepted: September 1, 2021 Article in press: September 1, 2021 Published online: October 26, 2021
Abstract
Recent studies have confirmed that β-adrenergic receptors (β-ARs) are expressed on the surface of osteoblasts and osteoclasts, and that the sympathetic nervous system can regulate bone metabolism by activating them. β-AR blockers (BBs) are commonly used in the treatment of cardiovascular diseases in the elderly. It is important to investigate whether BBs have a beneficial effect on bone metabolism in the treatment of cardiovascular diseases, so as to expand their clinical application. This article reviews the effects of BB on bone metabolism and the progress of clinical research.
Core Tip: β-Adrenergic receptors (β-ARs) are widely used clinically in senile cardiovascular diseases. As β-AR blockers (BBs) are involved in the regulation of bone metabolism, it is worth exploring they have beneficial effects on bone metabolism in the treatment of cardiovascular diseases. This article reviews the mechanisms of BBs in bone metabolism and its clinical applications.
